ViewsML Secures Funding to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform

ViewsML Secures Funding to Accelerate Commercialization of AI-Driven Virtual Biomarker Staining Platform

VANCOUVER, British Columbia, April 20, 2026 (GLOBE NEWSWIRE) -- ViewsML, a company building the computational layer for biomarker discovery by...

ViewsML Raises $4.9M for AI-Driven Virtual Biomarker Staining Platform

What You Should Know The Funding: ViewsML, a company building the computational layer for biomarker discovery, has closed an oversubscribed $4.9M seed round led by Wittington Ventures, with significant strategic participation from Mayo Clinic and Continuum Health Ventures, alongside repeat investors like RiSC Capital and Debiopharm.The Core Technology: ViewsML is building the world’s first virtual biomarker library. Using artificial intelligence…

ViewsML secures $4.9 million to help scientists virtually analyze tissue samples

ViewsML wants to make it easier for clinicians and scientists to extract insights from human tissue samples outside the laboratory with the help of AI. The Vancouver-based startup announced today that it has closed $4.9 million CAD in seed funding to execute on that vision and commercialize its platform.  ViewsML is developing AI models designed to derive biomarker insights—health indicators such as the presence of a certain nutrient in blood or…